K KalshiMarkets & Companies

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)

0 outcomesSettles —

Embed these odds

Paste this into any web page or blog post. The odds refresh every minute.

Theme
Preview
Favorite
—
Runner-up
—
single-outcome market
Biggest 24h move
—
odds steady over the last day
24h volume
$0
· $1 contracts

Current odds

one winner

All outcomes

0
OutcomeOdds24h change24h volumeOpen interest